Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 12/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
| ▸ | TNKS | O95271 | 1/20 | 0.48 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27747134 | 0.87 | PARP1 (0.55) | PARP1ALDH1A1CYP1A2TRPV1KMT2A | |
| SCHEMBL8154848 | 0.85 | TRPV1 (0.66) | ALDH1A1CYP1A2TRPV1KMT2AHSD17B10 | |
| SCHEMBL1312094 | 0.78 | TRPV1 (0.74) | ALDH1A1CYP1A2TRPV1KMT2A | |
| SCHEMBL896527 | 0.76 | JAK2 (0.54) | ALDH1A1CYP1A2TRPV1KMT2A | |
| SCHEMBL17942780 | 0.72 | MAOB (0.54) | ALDH1A1CYP1A2TRPV1KMT2AHSD17B10 | |
| SCHEMBL1735617 | 0.72 | TRPV1 (0.51) | ALDH1A1CYP1A2TRPV1KMT2A | |
| SCHEMBL3201877 | 0.72 | TRPV1 (0.51) | ALDH1A1CYP1A2TRPV1KMT2A | |
| SCHEMBL11076373 | 0.71 | KMT2A (0.58) | ALDH1A1CYP1A2TRPV1KMT2A | |
| SCHEMBL13462392 | 0.71 | ALDH1A1 (0.55) | ALDH1A1CYP1A2TRPV1KMT2A | |
| SCHEMBL3144214 | 0.71 | MEN1 (0.61) | ALDH1A1CYP1A2TRPV1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931681-B1 | SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | GLENMARK PHARMACEUTICALS SA (CH) | 2012-11-14 | — | — | EP | disclosed |
| US-20120277259-A1 | SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-11-01 | — | — | US | disclosed |
| US-20120041011-A1 | SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-02-16 | — | — | US | disclosed |
| US-20110021549-A1 | SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2011-01-27 | — | — | US | disclosed |
| US-7842703-B2 | Substituted benzofused derivatives and their use as vanilloid receptor ligands | GLENMARK PHARMACEUTICALS S.A. (CH) | 2010-11-30 | — | — | US | disclosed |
| US-20080269253-A1 | Substituted Benzofused Derivatives and Their Use as Vanilloid Receptor Ligands | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2008-10-30 | — | — | US | disclosed |
| EP-1931681-A1 | SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | Glenmark Pharmaceuticals S.A. (CH) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007042906-A1 | SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | GLENMARK PHARMACEUTICALS S.A. (US) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269253-A1 | Substituted Benzofused Derivatives and Their Use as Vanilloid Receptor Ligands | TRPV1, GPR17, TRPV6 | PARP1 3865/4885ALDH1A1 665/4885CYP1A2 1012/4885 |
| US-20120041011-A1 | SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | TRPV1, GPR17, TRPV6 | PARP1 3878/4885ALDH1A1 604/4885CYP1A2 949/4885 |
| US-20110021549-A1 | SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | TRPV1, GPR17, TRPV6 | PARP1 3878/4885ALDH1A1 604/4885CYP1A2 949/4885 |
| US-20120277259-A1 | SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | TRPV1, GPR17, TRPV6 | PARP1 3865/4885ALDH1A1 665/4885CYP1A2 1012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.